- Molecular NameFormoterol
- Synonymformoterol; Formoterol fumarate; Formoterolum [INN-Latin]
- Weight344.411
- Drugbank_IDDB00983
- ACS_NO73573-87-2
- Show 3D model
- LogP (experiment)2.083
- LogP (predicted, AB/LogP v2.0)1.32
- pka7.82; 8.53
- LogD (pH=7, predicted)-0.53
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.25
- LogSw (predicted, AB/LogsW2.0)12.75
- Sw (mg/ml) (predicted, ACD/Labs)0.54
- No.of HBond Donors4
- No.of HBond Acceptors6
- No.of Rotatable Bonds8
- TPSA90.82
- StatusFDA approved
- AdministrationOral, Inhalation
- PharmacologyA long-acting β2-agonist used in the management of asthma and/or chronic obstructive pulmonary disease (COPD).
- Absorption_valueN/A
- Absorption (description)After inhalation of formoterol, there is rapid absorption.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding50.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic demethylation and glucuronidation (CYP2D6, CYP2C19, CYP2C9 and CYP2A6 involved). Metabolism is mainly via direct glucuronidation and O-demethylation, and this is the main route of elimination. Formoterol is also sulfated to some extent to a sulfate conjugate.
- Half life10 h
- Excretion8 to 13% of an oral dose is excreted unmetabolised in urine (20% for intravenous administration and 24% for an inhaled dose). 62% of a total dose is recovered in urine with 24% as faeces.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityPossible side effects include tremors, headaches, palpitations, tachycardia, hypotension and hyperglycaemia. It is a poison by intraperitoneal and intravenous routes and moderately toxic by ingestion and subcutaneous routes.
- LD50 (rat)N/A
- LD50 (mouse)N/A